(Press-News.org) The Asian Fund for Cancer Research (AFCR) proudly recognizes the exceptional contributions of Dr. Yung-Chi Cheng, AFCR Scientific Advisory Board Member, and Henry Bronson Professor of Pharmacology and Medicine at Yale University. Dr. Cheng's unwavering commitment over the past thirty years has led to the establishment of Yiviva, a clinical-stage platform biotechnology company dedicated to developing transformative medicines targeting cancer and aging-related diseases.
AFCR was the early champion behind Dr. Yung-Chi Cheng's pursuit of applying a systems biology approach to treating cancer by harnessing the polychemical and multi-targeted benefits of medicinal plants—our long-term support fruit through Yiviva's new partnership with AstraZeneca China. This partnership connects Yiviva with AstraZeneca's Innovation Campus (iCampus), state-of-the-art facilities, expertise, and ecosystem to accelerate the development of innovative systems biology medicines by gaining insights from ancient medicines. It provides further validation of Dr. Cheng's pioneering approach to learn from traditional, experience-based medicines, using modern science to develop future medicines and have a profoundly positive impact on cancer patients.
AFCR was one of the early funders when Dr. Cheng first launched Yiviva, investing in his vision of "WE Medicine" – fusing Western and Eastern wisdom and science. Additional backing from AFCR empowered Yiviva's growth into a clinical-stage company developing botanical drugs against cancer. Yiviva's lead drug YIV-906 is currently in Phase IIb trials for hepatocellular carcinoma with a data readout expected in 2024. YIV-906 has been tested in multiple Phase I/II clinical trials in liver, pancreatic, colorectal, or rectal cancers, with early clinical research findings suggesting that YIV-906 could improve both efficacy and safety for standard treatments, prolong survival, and improve the quality of life for patients.
Dr. Cheng has a vision for developing multi-targeted, systems biology medicines powered by medicinal plants, which is now showing real promise to drive improved patient outcomes. Yiviva's expanding global ties underscore the vast potential of this research path. Sustained support from AFCR helped facilitate continued progress, now marked by Yiviva's collaboration with pharma leader AstraZeneca.
The agreement between Yiviva and AstraZeneca China marks a significant milestone for Yiviva. The collaboration aims to co-develop systems biology platforms and innovative botanical medicines, aligning with AFCR's mission to advance breakthrough cancer research in Asia and beyond. Dr. Cheng's vision of WE Medicine, harmonizing the best practices of both Western and Eastern medicine, aligns seamlessly with the collaborative efforts of Yiviva and AstraZeneca. The potential to create a new paradigm for systems biology drug development holds promise for patients worldwide.
Dr. Yung-Chi Cheng's achievements are a testament to the impact of sustained support for innovative research. AFCR is proud to have played a role in supporting his groundbreaking work, and we are excited to see Yiviva's strategic collaboration with AstraZeneca because of this collective effort," said Dr. Sujuan Ba, President and CEO of the Asian Fund for Cancer Research.
Yiviva's CEO, Peikwen Cheng, expressed gratitude for AFCR's early support, stating, "The seed investment from AFCR was instrumental in launching Yiviva, and we are thankful for their foresight and commitment to advancing cancer research. Today's collaboration with AstraZeneca is a testament to the impact of sustained support in driving innovation and breakthroughs."
About AFCR:
The Asian Fund for Cancer Research (AFCR) is a non-profit organization committed to advancing cancer research through strategic investments, collaborations, and partnerships. AFCR focuses on supporting innovative research initiatives with the potential to impact cancer outcomes in Asia and globally. For more information, please visit www.afcr.org.
About Yiviva:
Yiviva is a clinical-stage platform biotechnology company co-founded by Dr. Yung-Chi Cheng, dedicated to developing systems biology medicines for aging-related diseases, including cancer and inflammatory diseases. The company's strategic investors include the Asian Fund for Cancer Research and other key partners. For more information, please visit www.yiviva.com.
END
Asian Fund for Cancer Research (AFCR) commends Dr. Yung-Chi Cheng's three decades of pioneering research and celebrates Yiviva's recent partnership with AstraZeneca China
2024-02-21
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Teachers’ growth mindset appears more important than warmth
2024-02-21
PULLMAN, Wash. -- Students tend to like friendly teachers, but they like those who believe they can improve even more, new research indicates.
Students in a study still responded positively to instructors described as being cold but who also had a growth mindset, meaning they felt students’ ability in a subject could improve by working hard and trying different strategies. The opposite was also true: more participants reacted negatively to a warm, smiling teacher when they stated a fixed mindset, which is a belief that innate abilities cannot be changed, such as someone being naturally good at math.
“It's not enough to just be nice,” said lead author Makita ...
Older adults with a history of stroke at high risk of pandemic-induced depression
2024-02-21
Toronto, ON — A new longitudinal study from the University of Toronto highlights the substantial mental health toll of the COVID-19 pandemic on older adults with a history of stroke.
Researchers examined a sample of over 500 older adults with a history of stroke from the Canadian Longitudinal Study on Aging, a large dataset of older Canadians. Their findings indicated high levels of depression in this population during the COVID-19 pandemic.
“People who have experienced a stroke are already highly vulnerable to adverse mental health outcomes, such as depression,” said lead author Andie MacNeil, a research assistant at the University ...
Revealing what makes bacteria life-threatening
2024-02-21
Queensland researchers have discovered that a mutation allows some E. coli bacteria to cause severe disease in people while other bacteria are harmless, a finding that could help to combat antibiotic resistance.
Professor Mark Schembri and Dr Nhu Nguyen from The University of Queensland’s Institute for Molecular Bioscience and Associate Professor Sumaira Hasnain from Mater Research found the mutation in the cellulose making machinery of E. coli bacteria.
Professor Schembri said the mutation gives the affected E. coli bacteria the green light ...
Durham University scientists discover the real-life impacts of northern elephant seal bottleneck
2024-02-21
New research of northern elephant seals has revealed their reproductive and foraging success has been affected by a population bottleneck which nearly caused their extinction and could make them vulnerable as the environment changes in the future.
The northern elephant seal is an iconic species living along the very accessible Pacific coastline of Mexico and North America, hauling out on beaches to breed. For much of the 19th century, they were hunted for the oil derived from their blubber. They were thought extinct after the last few that could be found were taken in 1892.
Fortunately, around 20 had survived, and they made a remarkable comeback. Now less than 150 years later, ...
NIH study offers new clues into the causes of post-infectious ME/CFS
2024-02-21
In a detailed clinical study, researchers at the National Institutes of Health have found differences in the brains and immune systems of people with post-infectious myalgic encephalomyelitis/chronic fatigue syndrome (PI-ME/CFS). They also found distinct differences between men and women with the disease. The findings were published in Nature Communications.
“People with ME/CFS have very real and disabling symptoms, but uncovering their biological basis has been extremely difficult,” said Walter Koroshetz, M.D., director of NIH’s National Institute of Neurological Disorders and Stroke (NINDS). “This in-depth study of a small group of people found ...
Weedy rice gets competitive boost from its wild neighbors
2024-02-21
Rice feeds the world. But a look-alike weed has many ways of getting ahead.
Weedy rice is an agricultural pest with a global economic impact. It is an aggressive weed that outcompetes cultivated rice and causes billions of dollars in yield losses worldwide. In the U.S. alone, crop losses attributed to weedy rice could feed an additional 12 million people annually.
A study from Washington University in St. Louis offers new insights into genetic changes that give weedy rice its edge over cultivated rice in tropical regions of the world. Writing in Nature Communications, researchers ...
Butterfly and moth genomes mostly unchanged despite 250 million years of evolution
2024-02-21
The most extensive analysis of its kind reveals how butterfly and moth chromosomes have remained largely unchanged since their last common ancestor over 250 million years ago. This stability exists despite the incredible diversity seen today in wing patterns, sizes, and caterpillar forms across over 160,000 species globally.
Researchers from the Wellcome Sanger Institute and their collaborators at the University of Edinburgh analysed and compared over 200 high-quality chromosome-level genomes across butterflies and moths to better understand their evolutionary history.
They further uncovered rare groups of species that broke these genetic norms ...
Hepatocellular carcinoma incidence and mortality in the USA by sex, age, and race: A nationwide analysis of two decades
2024-02-21
Background and Aims
Over the past two decades, there has been a significant increase in the incidence of primary liver cancer in the USA, with higher rates observed in men. Its burden increases with age and disproportionately affects men, with mortality rates three times higher in men than in women. The higher incidence in men can be partially attributed to a greater prevalence of risk factors such as alcohol abuse and chronic HBV and HCV infections. A recent study of the Surveillance Epidemiology and End Results (SEER) database showed rising incidence and mortality of liver cancer in the USA from 1975 to ...
AGA now recommends fecal microbiota transplant for the majority of recurrent C. diff patients
2024-02-21
Bethesda, MD (Feb. 21, 2024) — In the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological Association recommends fecal microbiota transplant (FMT) for most patients with recurrent Clostridioides difficile (C. diff) infection.
“Using fecal microbiota transplant, we take stool from a healthy donor and transfer it to the colon of the person with recurrent C. diff, restoring balance to their gut microbiome,” explains guideline author Dr. Anne Peery. “FMT is a safe and effective treatment with enough scientific ...
Why are fish getting smaller as waters warm? It’s not their gills, finds study led by UMass Amherst
2024-02-21
February 21, 2024
Why Are Fish Getting Smaller as Waters Warm? It’s Not Their Gills, Finds Study Led by UMass Amherst
Biologists find no link between fish size and gill surface area—study suggests that models underlying some projections of future fisheries yields need to be reconsidered
AMHERST, Mass. – A collaborative team of scientists led by the University of Massachusetts Amherst recently found that there is no physiological evidence supporting a leading theory— which involves the surface area of fish gills —as to why many fish species are ...